Jeff Bezos, Amazon’s founder and CEO, said that reducing healthcare’s burden on the economy while improving outcomes for employees and their families would be worth the effort, and the 3 companies had the talented experts with fresh approaches and a long-term orientation that will be key to success.
Amazon, Berkshire Hathaway, and JPMorgan Chase announced that they will partner to form an independent healthcare company to serve their US employees, with the goal to improve US employee satisfaction while reducing overall costs, according to a press release.
The 3 companies said they will pursue this objective through an independent company that is “free from profit-making incentives and constraints.” The new entity will initially focus on technology to provide simplified, high-quality healthcare for their employees and their families, at a reasonable cost.” By bringing together 3 of the world’s leading organizations into this new construct, the group hopes to draw on its combined capabilities and resources to take a fresh approach to the critical healthcare challenges society faces today. Amazon is the world’s largest online retailer; Berkshire Hathaway is a holding company led by the billionaire investor Warren Buffett; and JPMorgan Chase is the largest bank in the United States.
Buffett compared the ballooning costs of healthcare to a “hungry tapeworm” feeding on the American economy. The companies say they are not approaching the problem with ready answers, but they are also not accepting the situation as inevitable. “We share the belief that putting our collective resources behind the country’s best talent can, in time, check the rise in health costs while concurrently enhancing patient satisfaction and outcomes,” said Buffett.
Jeff Bezos, Amazon’s founder and CEO, said that reducing healthcare’s burden on the economy while improving outcomes for employees and their families would be worth the effort, and the 3 companies had the talented experts with fresh approaches and a long-term orientation that will be key to success.
Chairman and CEO of JPMorgan Chase, Jamie Dimon, noted that the 3 companies have extraordinary resources and can potentially help all Americans. “Our people want transparency, knowledge, and control when it comes to managing their healthcare,” he added.
The three partners will focus on their collective 1.1 million employees first before opening to the general market. There are few details available about the new company, but the names of the 3 executives who will be leading the effort at the start were released: Marvelle Sullivan Berchtold, a managing director of JPMorgan Chase; Todd Combs, an investment officer of Berkshire Hathaway; and Beth Galetti, a senior vice president at Amazon.
Analysts said the new entity would face challenges such as assessing risk and other tasks that competing insurers are skilled at, but would be able to hire talent to provide for those needs. According to analyst Andrea Harris of Height Securities, the planned venture into healthcare announced by the 3 companies will target drug makers, wholesalers, pharmacy benefit managers (PBMs), and specialty pharmacies, because that is where scale and efficiencies can have the biggest impact. They are less likely to target managed care firms, where markets are too thin and setting up a care network is expensive and difficult.
Harris noted that if Amazon acquires Express Scripts—the last remaining large-market capitalization PBM—it would be in a strong position to drive down prices.
Mark Merritt, president and CEO of the Pharmaceutical Care Management Association, a trade organization representing American PBMs, is taking a wait-and-see approach. “If they have great ideas, we’d be glad to hear them,” he said. But he cautioned against companies involving themselves in complicated businesses that are not part of their core competency. “I think healthcare solutions are better solved on the back end rather than talking about what people’s aspirations are.”
Wall Street’s reaction to the announcement was a slide in the shares of CVS, UnitedHealth, Aetna, Anthem, and Express Scripts.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.